Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 10/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 9/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4676138 | 1.00 | ITGA4 (0.44) | ITGA4ITGB1HDAC1HDAC6MEN1 | |
| SCHEMBL4671784 | 0.90 | ITGA4 (0.47) | ITGA4ITGB1MEN1KMT2AMAPT | |
| SCHEMBL4671791 | 0.90 | ITGA4 (0.47) | ITGA4ITGB1MEN1KMT2AMAPT | |
| SCHEMBL6522255 | 0.89 | ITGA4 (0.41) | ITGA4ITGB1HDAC1HDAC6MEN1 | |
| SCHEMBL6522250 | 0.89 | ITGA4 (0.41) | ITGA4ITGB1HDAC1HDAC6MEN1 | |
| SCHEMBL4671381 | 0.85 | ITGA4 (0.42) | ITGA4ITGB1HDAC1HDAC6MEN1 | |
| SCHEMBL4671397 | 0.85 | ITGA4 (0.42) | ITGA4ITGB1HDAC1HDAC6MEN1 | |
| SCHEMBL4677538 | 0.83 | ITGB1 (0.47) | ITGA4ITGB1 | |
| SCHEMBL8359831 | 0.83 | ITGB1 (0.47) | ITGA4ITGB1 | |
| Hydrochloric Acid SCHEMBL4674445 | 0.82 | ITGB1 (0.47) | ITGA4ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414444-B1 | NOVEL IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VLA-4 ANTAGONISTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-04-09 | — | — | EP | disclosed |
| US-6962937-B2 | Imidazolidine derivatives, their preparation and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-11-08 | — | — | US | disclosed |
| US-20030109497-A1 | Novel imidazolidine derivatives, their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109497-A1 | Novel imidazolidine derivatives, their preparation and their use | VCAM1, ITGA1, ITGA4 | ITGA4 3/4885ITGB1 5/4885HDAC1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.